Elsevier

Cytokine

Volume 75, Issue 1, September 2015, Pages 68-78
Cytokine

Review Article
IL-4 and IL-13 signaling in allergic airway disease

https://doi.org/10.1016/j.cyto.2015.05.014Get rights and content

Abstract

Aberrant production of the prototypical type 2 cytokines, interleukin (IL)-4 and IL-13 has long been associated with the pathogenesis of allergic disorders. Despite tremendous scientific inquiry, the similarities in their structure, and receptor usage have made it difficult to ascertain the distinct role that these two look-alike cytokines play in the onset and perpetuation of allergic inflammation. However, recent discoveries of differences in receptor distribution, utilization/assembly and affinity between IL-4 and IL-13, along with the discovery of unique innate lymphoid 2 cells (ILC2) which preferentially produce IL-13, not IL-4, are beginning to shed light on these mysteries. The purpose of this chapter is to review our current understanding of the distinct roles that IL-4 and IL-13 play in allergic inflammatory states and the utility of their modulation as potential therapeutic strategies for the treatment of allergic disorders.

Introduction

Allergic asthma is a chronic inflammatory disease of the lung, which has been on the rise in recent decades. Currently asthma affects over 300 million people and one of every 250 deaths worldwide is attributed to this disease. Asthma is a reversible airway disease characterized by airway hyperresponsiveness, airway inflammation, and airway remodeling (i.e. mucus cell metaplasia, smooth muscle thickening, sub-epithelial fibrosis) and the main pathophysiological manifestation of the disease-airway hyperresponsiveness. Since the groundbreaking discovery of distinct CD4+ T cell subsets in the late 1980s [1], Th2 cytokine producing cells have been implicated in the pathogenesis of asthma. Indeed, a tremendous amount of evidence in both humans and animal models support a role for Th2 cells in the development of the prominent features of the allergic diathesis [2]. In deciphering the mechanisms by which Th2 cell derived cytokines regulate asthma pathogenesis, extensive efforts have been devoted to defining the role of the prototypical Th2 cytokines, IL-4 and IL-13. As IL-4 and IL-13 are encoded by adjacent genes (chr 5q in humans and chr11 in mice) that share a number of regulatory elements (GATA-3) and transmit signals through a shared functional receptor complex (IL-4Rα/IL-13Rα1), it was originally assumed that they would serve redundant functions in the pathogenesis of allergic asthma [3]. However, despite their many similarities, a series of in vivo functional experiments utilizing mice deficient in cytokines, cytokine-producing cells or lacking specific receptor subunits have shown that IL-4 and IL-13 play distinct roles in allergic asthma in vivo. In particular, IL-4, through its role in regulating Th2 cell proliferation and survival and IgE synthesis has been shown to be essential in the initiation of allergic airway responses and humoral responses, but it does not regulate AHR, mucus production, or subepithelial fibrosis in vivo in the context of allergic inflammation [4], [5], [6], [7], [8], [9], [10]. In contrast, its look-a-like, IL-13 is thought to play a more important role in the effector phase of the response and to be sufficient to induce the main manifestations of allergic disease including AHR, mucus production, airway smooth muscle alterations, and sub-epithelial fibrosis [11], [12], [13], [14], [15]. The precise mechanism(s) by which these two cytokines regulate distinct features of the allergic response, and how these actions either individually or in concert induce the pathophysiological manifestations of disease, still remain a mystery. Herein, we review recent insights into the potential mechanisms underlying their distinct roles in the asthmatic phenotype, the mechanisms by which IL-13 signaling plays a central role in regulating the effector phase of the disease, and the potential of modulating these cytokines for therapeutic benefit in asthma (see Fig. 1, Fig. 2, Fig. 3).

Section snippets

Mechanisms of distinct roles for IL-4 and IL-13 in allergic inflammation

Although the exact mechanisms by which IL-4 and IL-13 mediate different aspects of the asthmatic phenotype are not totally understood, studies examining the contributions of the four receptor chains (IL-4Rα, IL-13Rα1, γc, IL-13Rα2) which make up the type I and type II IL-4R complexes are providing some clues (Fig. 1). IL-4 signaling is initiated via two types of heterodimeric transmembrane receptor complexes: the type I receptor, which exclusively binds IL-4 and is comprised of IL-4Rα and γc

Mechanism(s) of IL-13 regulation of the effector phase of the allergic response

With the preponderance of evidence continuing to support a pivotal role for IL-13 in allergic disorders, attention is now turned toward understanding the mechanisms by which this cytokine may mediate the pathophysiological features of allergic disease. The emerging paradigm is that IL-13 induces features of the allergic response via a complex array of actions on resident airway cells. Below we review our current understanding of the mechanisms by which IL-13 regulates: (1) mucus cell

IL-4 and IL-13 in human asthma

The importance of IL-4 and IL-13 in allergic asthma in humans is supported by numerous reports of exaggerated IL-4 and IL-13 production in asthma. In asthma, both message and protein levels of both cytokines are elevated in bronchial biopsy specimens and BAL cells from allergic individuals when compared with those of control subjects [3], [106]. Conversely, IL-13 levels are reduced in patients with asthma undergoing allergen desensitization treatment regimes or steroid treatment. Moreover, a

Clinical trials targeting IL-4/IL-13 signaling in asthma

Based on the preponderance of evidence implicating IL-4 and IL-13 in mediating asthma pathophysiology, clinical trials are currently underway to investigate the blockade of IL-4, IL-13 and/or both in the treatment of asthma. One of the first studies was designed to evaluate the efficacy of blocking both IL-4 and IL-13 signaling with a recombinant human soluble interleukin-4 receptor on asthma. Although the study was small, it suggested that IL-4Rα blockade might improve FEV1 in asthmatics [117]

Conclusion

In conclusion, the preponderance of information generated in animal models of asthma support the conclusion that the type II cytokines IL-4 and IL-13, in tandem, play an important role in the pathogenesis of allergic asthma. IL-4 playing a pivotal role in Th2 cell proliferation and cytokine production and IgE synthesis, while IL-13 plays a pivotal role in the pathological features of disease (mucus production, AHR, and collagen deposition). Although we do not fully understand the mechanisms by

Acknowledgements

The authors acknowledge support from the following Grants: RO1AI083315, U19AI070235 to MWK, and NIEHST32ES007141 to N. Gour.

References (125)

  • M.Y. Viksman

    Expression of activation markers on alveolar macrophages in allergic asthmatics after endobronchial or whole-lung allergen challenge

    Clin Immunol

    (2002)
  • F. Kirstein

    Expression of IL-4 receptor alpha on smooth muscle cells is not necessary for development of experimental allergic asthma

    J Allergy Clin Immunol

    (2010)
  • J.K. Bentley

    Periostin is required for maximal airways inflammation and hyperresponsiveness in mice

    J Allergy Clin Immunol

    (2014)
  • S.A. Shore

    Direct effects of Th2 cytokines on airway smooth muscle

    Curr Opin Pharmacol

    (2004)
  • T.R. Mosmann

    Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins

    J Immunol

    (1986)
  • M. Wills-Karp

    Immunologic basis of antigen-induced airway hyperresponsiveness

    Annu Rev Immunol

    (1999)
  • M. Wills-Karp

    Interleukin-13 in asthma pathogenesis

    Immunol Rev

    (2004)
  • A.J. Coyle

    Interleukin-4 is required for the induction of lung Th2 mucosal immunity

    Am J Respir Cell Mol Biol

    (1995)
  • G. Brusselle

    Allergen-induced airway inflammation and bronchial responsiveness in wild-type and interleukin-4-deficient mice

    Am J Respir Cell Mol Biol

    (1995)
  • S.H. Gavett

    Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice

    Am J Physiol

    (1997)
  • D.B. Corry

    Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity

    J Exp Med

    (1996)
  • W.R. Henderson et al.

    Soluble IL-4 receptor inhibits airway inflammation following allergen challenge in a mouse model of asthma

    J Immunol

    (2000)
  • K. Dabbagh

    IL-4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo

    J Immunol

    (1999)
  • M. Wills-Karp

    Interleukin-13: central mediator of allergic asthma

    Science

    (1998)
  • G. Grunig

    Requirement for IL-13 independently of IL-4 in experimental asthma

    Science

    (1998)
  • Z. Zhu

    Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production

    J Clin Invest

    (1999)
  • D.C. Webb

    Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity

    J Immunol

    (2000)
  • C.L. Emson

    Interleukin (IL)-4-independent induction of immunoglobulin (Ig)E, and perturbation of T cell development in transgenic mice expressing IL-13

    J Exp Med

    (1998)
  • D.A. Kuperman

    Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma

    Nat Med

    (2002)
  • D.A. Kuperman et al.

    Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma

    Curr Mol Med

    (2008)
  • N.M. Heller

    Type I IL-4Rs selectively activate IRS-2 to induce target gene expression in macrophages

    Sci Signal

    (2008)
  • D. Kuperman

    Signal transducer and activator of transcription factor 6 (Stat6)-deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production

    J Exp Med

    (1998)
  • K. Nelms

    The IL-4 receptor: signaling mechanisms and biologic functions

    Annu Rev Immunol

    (1999)
  • A. Munitz

    Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha1 and the type II IL-4 receptor in asthma pathogenesis

    Proc Natl Acad Sci USA

    (2008)
  • N.M. Heller

    IL-4 engagement of the type I IL-4 receptor complex enhances mouse eosinophil migration to eotaxin-1 in vitro

    PLoS ONE

    (2012)
  • F. Sheikh

    The interleukin-13 receptor-alpha1 chain is essential for induction of the alternative macrophage activation pathway by IL-13 but Not IL-4

    J Innate Immun

    (2015)
  • H.E. Liang

    Divergent expression patterns of IL-4 and IL-13 define unique functions in allergic immunity

    Nat Immunol

    (2012)
  • D.R. Neill

    Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity

    Nature

    (2010)
  • A.E. Price

    Systemically dispersed innate IL-13–expressing cells in type 2 immunity

    Proc Natl Acad Sci USA

    (2010)
  • F.D. Finkelman

    Suppressive effect of IL-4 on IL-13-induced genes in mouse lung

    J Immunol

    (2005)
  • C.C. Lewis

    Unique and overlapping gene expression patterns driven by IL-4 and IL-13 in the mouse lung

    J Allergy Clin Immunol

    (2009)
  • P. Dasgupta

    Absence of the common gamma chain (gamma(c)), a critical component of the Type I IL-4 receptor, increases the severity of allergic lung inflammation

    PLoS ONE

    (2013)
  • N. Wood

    Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2

    J Exp Med

    (2003)
  • S. Fichtner-Feigl

    IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis

    Nat Med

    (2006)
  • C.G. Lee

    Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis

    J Exp Med

    (2009)
  • Y. Tabata

    Allergy-driven alternative splicing of IL-13 receptor alpha2 yields distinct membrane and soluble forms

    J Immunol

    (2006)
  • W. Chen

    IL-13R alpha 2 membrane and soluble isoforms differ in humans and mice

    J Immunol

    (2009)
  • M. O’Toole

    A novel and sensitive ELISA reveals that the soluble form of IL-13R-alpha2 is not expressed in plasma of healthy or asthmatic subjects

    Clin Exp Allergy

    (2008)
  • W. Chen

    IL-13 receptor alpha2 contributes to development of experimental allergic asthma

    J Allergy Clin Immunol

    (2013)
  • D. Mandal et al.

    Elevated IL-13Ralpha2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway

    Inflamm Bowel Dis

    (2010)
  • Cited by (351)

    View all citing articles on Scopus
    View full text